海外配电市场拓展
Search documents
三星医疗(601567):配电出海持续高景气,电表新规落地带动价格修复
Guoxin Securities· 2025-11-11 07:06
Investment Rating - The investment rating for the company is "Outperform the Market" [5][3]. Core Views - The company has experienced a 16% decline in performance over the first three quarters, with revenue at 11.08 billion yuan, a year-on-year increase of 6.19%, and a net profit of 1.528 billion yuan, down 15.85% year-on-year [9][3]. - The company is expected to gradually recover over the next six months as the negative factors in the domestic electric meter, distribution, and photovoltaic industries are largely exhausted [2][21]. - The recent opening of the third batch of electric meter tenders by the State Grid has led to a noticeable price recovery, benefiting leading electric meter companies [2][21]. - The company has a robust order backlog, with total orders amounting to 17.914 billion yuan, a year-on-year increase of 14.69%, and overseas distribution orders at 2.169 billion yuan, up 125.45% year-on-year [22][2]. Financial Performance Summary - For the first three quarters, the company reported a revenue of 11.08 billion yuan, with a gross margin of 28.46%, down 7.75 percentage points year-on-year, and a net margin of 13.60%, down 3.87 percentage points year-on-year [9][21]. - In Q3 alone, the company achieved a revenue of 3.108 billion yuan, a year-on-year decrease of 9.56% and a quarter-on-quarter decrease of 28.42%, with a net profit of 298 million yuan, down 55.22% year-on-year and 59.74% quarter-on-quarter [21][17]. - The company has adjusted its profit forecast for 2025-2027, expecting net profits of 1.875 billion, 2.473 billion, and 3.072 billion yuan respectively, with corresponding PE ratios of 20, 15, and 12 times [3][22].
三星医疗(601567):2025年中报点评:提质增效效果显著,业绩基本符合市场预期
Soochow Securities· 2025-08-22 05:26
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in the first half of 2025 is in line with market expectations, with significant improvements in quality and efficiency [8] - The company has achieved robust growth in its power distribution business, particularly in overseas markets, which is becoming a key growth driver [8] - The rehabilitation hospital business faces some pressure, but long-term demand remains strong [8] - The company has effectively controlled costs, leading to a notable reduction in expenses [8] - The long-term outlook for the overseas power distribution market is positive, with strong competitive advantages [8] Financial Summary - Total revenue for 2023 is projected at 11,463 million, with a year-on-year growth of 25.99% [1] - Net profit attributable to shareholders for 2023 is expected to be 1,904 million, reflecting a year-on-year increase of 100.79% [1] - The earnings per share (EPS) for 2023 is estimated at 1.35 yuan, with a price-to-earnings (P/E) ratio of 18.20 [1] - The company anticipates total revenue of 18,034 million in 2025, with a year-on-year growth of 23.51% [1] - The net profit attributable to shareholders for 2025 is projected at 2,511 million, with a year-on-year growth of 11.14% [1] - The EPS for 2025 is expected to be 1.79 yuan, with a P/E ratio of 13.80 [1]